Clinical features of lung adenocarcinoma cases. Patient clinical information and tumor characteristics for recurrent and non-recurrent lung adenocarcinoma cases (n = 20)

Patient ID	Recurrence	Recurrence site	Predominant Histological Pattern	Age	Sex	T	N	Max. Dimension (cm)	Stage	Adjuvant chemo-therapya	Adjuvant radiation	Smoking	Mutation	Survival (Months)
P1	NA		Acinar	71	F	1	0	2.8	IA	No	No	CS	KRAS	96
P2	No		Acinar	82	F	2	0	3	IB	No	No	EX	EGFR	81
P3			Acinar	68	F	1	0	1.8	IA	No	No	NS	WT	77
P4			Acinar	57	F	2	1	2.8	IIB	Yes	No	CS	KRAS	86
P5			Acinar	67	F	2	1	3.2	IIB	Yes	No	CS	WT	88
P6			Acinar	71	F	2	0	3.1	IB	No	No	NS	WT	26
P7			Acinar	70	M	1	0	2.3	IA	No	No	CS	NA	95
P8			Mucinous	86	F	2	0	3.2	IB	No	No	NS	KRAS	92
P9			Acinar	82	F	3	0	2.7	IIB	No	No	NS	EGFR	98
P10	Yes	distant	Acinar	73	F	4	1	2.8b	IIA	No	No	CS	NA	63
P11		distant	Acinar	77	F	2	0	3.4	IB	No	No	NS	WT	13
P12		distant	Papillary	90	F	2	1	4.5	IIB	No	No	EX	WT	30
P13		local	Mucinous	77	F	1	0	2.5	IA	No	No	NS	KRAS	76
P14		distant	Acinar	53	F	2	2	7	IIIA	No	No	CS	KRAS	3
P15		local and distant	Papillary	60	F	2	1	2.5	IIB	Yes	No	EX	EGFR	77
P16		local and distant	Acinar	72	F	2	0	4.5	IB	No	No	CS	WT	61
P17		distant	Acinar	58	M	2	1	2.5	IIB	No	No	EX	WT	30
P18		distant	Micro-papillary	66	M	2	2	3.5	IIIA	Yes	No	NS	EGFR	58
P19		distant	Papillary	77	F	2	1	4	IIB	No	No	NS	EGFR	46
P20		distant	Acinar	78	F	1	0	1.2	IA	No	No	CS	KRAS	37

M Male, F Female, CS Current Smoker, EX Former Smoker, NS Never Smoker

^aAdjuvant chemotherapy: cisplatin-vinorelbine, 4 cycles except for patient P4 who received 3 cycles of cyclophosphamide, doxorubicin and was then on tamoxifen because of synchronous breast cancer

^bplus four additional carcinomas removed, giving the final T4 classification